Cannabis finds its way into treatment of Crohn's disease

Pharmacology

Volumn 93, Issue 1-2, 2014, Pages 1-3

  Schicho, Rudolf ^a   Storr, Martin ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cannabinoids; Inflammatory bowel disease; Prospective study

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; CANNABINOID RECEPTOR 2; CANNABIS; ENDOCANNABINOID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TETRAHYDROCANNABINOL; TRANSIENT RECEPTOR POTENTIAL CATION CHANNELS SUBFAMILY V RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABIGEROL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; TETRAHYDROCANNABIVARINE;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL (TOPIC); COLITIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE COURSE; ENTERITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; BRAIN; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG TARGETING; INFLAMMATION; MEDIATOR RELEASE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CANNABINOIDS; CANNABIS; CROHN DISEASE; HUMANS;

EID: 84896131810     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000356512     Document Type: Review

References (10)

1. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM: Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013; 11: 1276-1280.
2. Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM: Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J 2011; 13: 455-458.
3. Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H: Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23: 891-896.
4. Di Sabatino A, Battista N, Biancheri P, Rapino C, Rovedatti L, Astarita G, Vanoli A, Dainese E, Guerci M, Piomelli D, Pender SL, MacDonald TT, Maccarrone M, Corazza GR: The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol 2011; 4: 574-583.
5. Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de Fonseca F, Andreu M: Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 2009; 4:e6893.
6. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S: Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005; 129: 437-453. (Pubitemid 41096632)
7. Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS: Cannabinoid receptor-2 (CB 2 ) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 2012; 258: 256-267.
8. Izzo AA, Sharkey KA: Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126: 21-38.
9. Alhouayek M, Muccioli GG: The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 2012; 18: 615-625.
10. Cluny NL, Keenan CM, Duncan M, Fox A, Lutz B, Sharkey KA: Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB 1/CB 2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther 2010; 334: 973-980.